GlassScriptPhysician profile
Benjamin H Trichon
NPI 1871599860
$37,297.75
in general payments reported to CMS, 2019-2025
25 companies · $607 in 2025
The $607 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $8,319 · 2021: $5,852 · 2022: $1,035 · 2023: $1,756 · 2024: $1,926 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,279 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,278.56 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $17,750.72 | 2019-2024 | Opsumit, Uptravi |
| Novartis Pharmaceuticals Corporation | $9,834.00 | 2019-2024 | |
| Abbott Laboratories | $6,861.79 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Heartmate Touch |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $444.14 | 2019-2025 | Lifevest |
| Pfizer INC. | $356.72 | 2019-2024 | |
| Abiomed | $314.47 | 2019-2022 | |
| United Therapeutics Corporation | $245.90 | 2019-2025 | Tyvaso, Remodulin, Orenitram |
| Merck Sharp & Dohme LLC | $243.35 | 2023-2025 | Winrevair |
| Impulse Dynamics (USA) INC. | $196.72 | 2024 | Optimizer |
| Cvrx, INC. | $147.13 | 2024-2025 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $139.14 | 2019-2023 | Amvuttra |
| Astrazeneca Pharmaceuticals LP | $138.45 | 2023-2024 | Farxiga, Wainua |
| Atricure, INC. | $134.96 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $129.71 | 2022-2024 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.07 | 2019-2024 | Jardiance |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $83.29 | 2024 | |
| Boston Scientific Corporation | $48.20 | 2024 | Watchman Flx |
| Novo Nordisk INC | $40.47 | 2024 | Ozempic, Wegovy |
| Kiniksa Pharmaceuticals International, Plc | $24.89 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $23.39 | 2024 | |
| W. L. Gore & Associates, INC. | $16.24 | 2025 | Gore Cardioform Septal Occluder |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Trichon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.